Abbott’s Xience Stent Launch Drives Sales, Stock Gains In Third Quarter

Abbott's Xience has become the leading drug-eluting coronary stent in the U.S. since its debut July 2, controlling a market share percentage in the "mid-to-upper 20s," according to the company